Bellco Capital
VC Fund
Los Angeles, United States
Bellco Capital is a private equity firm based in Los Angeles, California.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Bellco Capital invests in
Stages Bellco Capital invests in
Countries Bellco Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Biotechnology 6 (46%)
- Therapeutics 4 (31%)
- Health Care 3 (23%)
- Medical 2 (15%)
- Baby 1 (8%)
Stage
- Series A 3 (23%)
- Private Equity 3 (23%)
- Series B 2 (15%)
- Seed 1 (8%)
- Series C 1 (8%)
Country
- United States 7 (54%)
- The Netherlands 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Arie Belldegrun
Co-Founder and Chairman
|
Co-Founder and Chairman | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M / May 13, 2024 | |
|
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M / Series C / May 13, 2024 | |
|
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M / Series C / May 13, 2024 | |
Breakthrough Properties
|
Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. | Private Equity / Jan 01, 2023 | |
First Media
|
First Media is dedicated to inspiring the do-it-all millennial woman with four media properties focused on clever ways to live better. Its growing communities of 115 million fans worldwide play with their food with So Yummy, life hack with Blossom, make beauty a breeze with Blusher and watch baby blossom on BabyFirst. Online, fans generate 1.5billion views and 50+ million engagements each month. | Private Equity / Jan 01, 2022 | |
|
ByHeart
|
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $90M / Series B / Jul 26, 2021 | |
IconOVir Bio
|
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. | $77M / Series A / Jan 05, 2021 | |
Cell Design Labs
|
Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power,precision, safety and durability | Private Equity / Jan 01, 2021 | |
Dewpoint Therapeutics
|
Dewpoint Therapeutics is a biotech company which develop a drug platform that targets biomolecular condensates. | $77M / Series B / Sep 29, 2020 | |
Neogene Therapeutics
|
Neogene Therapeutics provides cancer patients with T cell therapies targeting mutated proteins called neo-antigens. The company is developing novel technologies to enable the engineering of ‘designer T cells’ with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.Neogene's platform allows for theisolation of neo-antigen specific TCR genes from tumor biopsies that are routinely obtained from cancer patients during treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies frequently express TCRs specific for mutated proteins found in cancer cells (neo-antigens). The company’s proprietary technology uses state-of-the-art DNA sequencing, DNA synthesis and genetic screening tools to identify such neo-antigen specific T cell receptor genes within tumor biopsies with high sensitivity, specificity and at scale. | $110M / Series A / Sep 14, 2020 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bellco Capital invest in?
Bellco Capital invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Private Equity stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bellco Capital?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bellco Capital?
The team at Bellco Capital includes Arie Belldegrun (Co-Founder and Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
